Approximate time | COVID lineage | Symptoms/disease | Treatment |
---|---|---|---|
2019 | None | Hodgkin’s Lymphoma | ABVD chemotherapy followed by GDP chemotherapy and autologous stem cell transplant |
February 2021 | None | Hodgkin’s Lymphoma disease progression, Graft versus host disease | Allogenic stem cell transplant, prednisome |
March 2021 | B.1.1.176 | Mild upper respiratory tract infection, Epstein–Barr viral reactivation | Bamlanivimab |
April 2021 | B.1.1.176 | Post-transplant lymphoproliferative disorder | Rituximab |
June 2021 | B.1.1.176 | Â | Â |
June 2021 | B.1.1.176 | Â | Â |
July 2021 | B.1.1.176 | Progressive cough and shortness of breath | Remdesivir, dexamethasone, Bamlanivimab |
July 2021 | B.1.1.176 | Â | Â |
July 2021 | B.1.1.176 | Â | Â |
August 2021 | B.1.1.176 | Â | Â |
January 2022 | Not determined | Hospitalized with shortness of breath and bilateral lung consolidations | Sotrovimab, remdesivir, dexamethasone |
May 2022 | B.1.1.176/BA.1 | Â | Â |
June 2022 | BA.2.9 | Â | Â |
June 2022 | BA.2.9 | Â | Â |
June 2022 | Â | Death | Â |